Reduced basal forebrain atrophy progression ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Reduced basal forebrain atrophy progression in a randomized donepezil trial in prodromal alzheimer's disease
Author(s) :
Cavedo, Enrica [Auteur]
Grothe, Michel J. [Auteur]
Colliot, Olivier [Auteur]
Lista, Simone [Auteur]
Chupin, Marie [Auteur]
Dormont, Didier [Auteur]
Houot, Marion [Auteur]
Lehericy, Stéphane [Auteur]
Teipel, Stefan J. [Auteur]
Dubois, Bruno [Auteur]
Hampel, Harald [Auteur]
Pasquier, Florence [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Delmaire, Christine [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Grothe, Michel J. [Auteur]
Colliot, Olivier [Auteur]
Lista, Simone [Auteur]
Chupin, Marie [Auteur]
Dormont, Didier [Auteur]
Houot, Marion [Auteur]
Lehericy, Stéphane [Auteur]
Teipel, Stefan J. [Auteur]
Dubois, Bruno [Auteur]
Hampel, Harald [Auteur]
Pasquier, Florence [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Delmaire, Christine [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Journal title :
Scientific Reports
Abbreviated title :
Sci Rep
Volume number :
7
Pages :
11706
Publication date :
2017-09-15
ISSN :
2045-2322
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer's disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex ...
Show more >Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer's disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temporal sequence of topographical pathology associated with AD. We studied the effect of one-year Donepezil treatment on the rate of BFCS atrophy in prodromal AD patients using a double-blind, randomized, placebo-controlled trial of Donepezil (10 mg/day). Reduced annual BFCS rates of atrophy were found in the Donepezil group compared to the Placebo treated arm. Secondary analyses on BFCS subregions demonstrated the largest treatment effects in the Nucleus Basalis of Meynert (NbM) and the medial septum/diagonal band (Ch1/2). Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2).Show less >
Show more >Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer's disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temporal sequence of topographical pathology associated with AD. We studied the effect of one-year Donepezil treatment on the rate of BFCS atrophy in prodromal AD patients using a double-blind, randomized, placebo-controlled trial of Donepezil (10 mg/day). Reduced annual BFCS rates of atrophy were found in the Donepezil group compared to the Placebo treated arm. Secondary analyses on BFCS subregions demonstrated the largest treatment effects in the Nucleus Basalis of Meynert (NbM) and the medial septum/diagonal band (Ch1/2). Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2).Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Submission date :
2019-11-27T13:36:44Z
2021-05-17T08:18:12Z
2021-08-30T13:23:34Z
2024-01-10T14:57:57Z
2021-05-17T08:18:12Z
2021-08-30T13:23:34Z
2024-01-10T14:57:57Z